This systematic review looked at how PARP inhibitors work inside glioblastoma tumor cells and which patients might benefit most. The study focused on adult patients receiving these drugs alongside standard surgery, radiation, and chemotherapy. Researchers assessed the best candidates for treatment based on molecular profiling to understand potential benefits.
The main finding indicates that the effectiveness of these drugs is strongly influenced by their ability to cross the blood-brain barrier. Additionally, the presence of tumor resistance mechanisms further limits their impact. Consequently, several PARP inhibitors investigated in combination with standard therapy failed to show significant clinical improvement.
Safety concerns were not specifically reported in the available data for this review. However, the main reason to be careful is that local recurrence is almost inevitable, and treatment options for relapsed disease remain limited. Readers should understand that patient selection using molecular biomarkers and the timing of drug administration are crucial for maximizing any potential therapeutic benefit.